Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
View Patent ↗Provided herein are compositions and methods for the treatment of tendinopathies, such as tenosynovitis, tendinosis or tendinitis, including Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis or “tennis elbow,” medial epicondylitis or “golfer's elbow,” plantar fasciitis, and rotator cuff tendinopathy, and in particular to methods for the treatment of tendinopathies by administering compositions comprising platelet-derived growth factor (PDGF).
1. A method of treating a tendinopathy comprising administering to an affected site an effective amount of a composition comprising a PDGF and a buffer, wherein the effective amount of the composition comprises between about 75 μg and about 7,500 μg of PDGF per dose, and further wherein the administration to an affected site comprises a single intra-tendon injection.
2. The method of claim 1 , wherein the tendinopathy is a tendinosis.
3. The method of claim 1 , wherein the tendinopathy is a tendinitis.
4. The method of claim 1 , wherein the tendinopathy is a tenosynovitis.
5. The method of claim 1 , wherein the PDGF is selected from the group consisting of PDGF-AA, PDGF-BB, PDGF-AB, PDGF-CC, and PDGF-DD.
6. The method of claim 5 , wherein the PDGF comprises PDGF-BB.
7. The method of claim 6 , wherein the effective amount of the composition comprises between about 500 μg to about 1,000 μg of PDGF-BB per dose.
8. The method of claim 6 , wherein the effective amount of the composition comprises between about 5,000 μg to about 7,500 μg of PDGF-BB per dose.
9. The method of claim 6 , wherein the effective amount of the composition comprises between about 450 μg to about 3000 μg of PDGF-BB per dose.
10. The method of claim 6 , wherein the effective amount of the composition comprises between about 400 μg to about 1000 μg of PDGF-BB per dose.
11. The method of claim 6 , wherein the effective amount of the composition comprises between about 500 μg to about 900 μg of PDGF-BB per dose.
12. The method of claim 6 , wherein the effective amount of the composition comprises between about 600 μg to about 800 μg of PDGF-BB per dose.
13. The method of claim 6 , wherein the effective amount of the composition comprises between about 650 μg to about 750 μg of PDGF-BB per dose.
14. The method of claim 6 , wherein the effective amount of the composition comprises about 700 μg of PDGF-BB per dose.
15. The method of claim 5 , wherein the PDGF comprises recombinant human (rh) PDGF-BB.
16. The method of claim 1 , wherein the composition has a volume of about 1.0 to about 2.0 ml per dose.
17. The method of claim 1 , wherein the composition has a volume of about 1.5 ml per dose.
18. The method of claim 1 , wherein the buffer is selected from the group consisting of phosphate-buffered saline (PBS), sodium acetate, ammonium acetate, acetic acid, citric acid, sodium citrate, tris(hydroxymethyl)aminoethane (tris), N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), 3-(N-morpholino) propane sulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N-(2-acetamido)iminodiacetic acid (ADA), piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES), and N-(2-acetamido)-2-aminoethanesulfonic acid(ACES).
19. The method of claim 18 , wherein the buffer is sodium acetate.
20. The method of claim 19 , wherein the sodium acetate is at a concentration between about 10 mM and about 100 mM.
21. The method of claim 20 , wherein the sodium acetate is at a concentration of about 20 mM.
22. The method of claim 1 , wherein the composition has a pH between about 4.0 and about 7.0.
23. The method of claim 22 , wherein the composition has pH of about 6.
24. The method of claim 1 , wherein the tendinopathy is selected from the group consisting of Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis, medial epicondylitis, plantar fasciitis, and rotator cuff tendinopathy.
25. The method of claim 1 , wherein the tendinopathy is lateral epicondylitis.
26. The method of claim 1 , wherein the composition is administered by a single injection once a week for four weeks.